title: Hemolytic uremic syndrome following Campath-1H induction.
abstract: Hemolytic uremic syndrome (HUS) is a rare complication following solid organ transplantation. We report on a patient who underwent renal transplantation using Campath-1H induction and tacrolimus maintenance therapy who developed HUS, which was managed by plasma exchange and switch to Rapamycin. However, graft function could not be restored.
authors.affiliation: Department of General and Transplant Surgery, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: Hugo
authors.initials: H
authors.lastname: Bonatti
authors.forename: Gerald
authors.initials: G
authors.lastname: Brandacher
authors.forename: Claudia
authors.initials: C
authors.lastname: Boesmueller
authors.forename: Micol
authors.initials: M
authors.lastname: Cont
authors.forename: Paul
authors.initials: P
authors.lastname: Hengster
authors.forename: Alexander R
authors.initials: AR
authors.lastname: Rosenkranz
authors.forename: Jens
authors.initials: J
authors.lastname: Krugmann
authors.forename: Raimund
authors.initials: R
authors.lastname: Margreiter
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D010951:Plasma Exchange; D020123:Sirolimus / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D020123:Sirolimus; D016559:Tacrolimus